Table 1. Comparison of a history of CSC and other key background factors among patients with tAMD, those with PCV and the control subjects.
| Control (n=150) | tAMD (n=89) | PCV (n=138) | P-value (univariate) | P-value (multivariate) | |
|---|---|---|---|---|---|
| Age, mean (SD) | 71.2 (8.2) | 70.8 (8.8) | 70.5 (7.4) | 0. 60 | 0.76 |
| Male, n (%) | 105 (70) | 70 (78.7) | 105 (76.1) | 0.27 | 0.50 |
| CSC, n (%) | 0 (0.0) | 2 (2.3) | 15 (10.9) | <0.0001 | <0.0001 |
| Systemic steroid, n (%) | 9 (6.0) | 2 (2.3) | 5 (3.6) | 0. 34 | 0.44 |
| Hypertension, n (%) | 65 (43.3) | 44 (49.4) | 57 (41.3) | 0.47 | 0.64 |
| Smoking (>10 pack-years), n (%) | 58 (38.7) | 60 (60.1) | 83 (60.1) | <0.0001 | <0.0001 |
Abbreviations: CSC, central serous chorioretinopathy; PCV, polypoidal choroidal vasculopathy; tAMD; typical age-related macular degeneration.